International access
Cancer treatment in Australia
A care system with many early- to late-phase clinical studies.
Orientation information, not an access guarantee
Facilities
Public-reference profiles
This list does not state partnership, quality, schedule, price, or international patient acceptance.
NO DATA
No facility profile has passed the public-reference model for this country yet.
Public registry
Recorded clinical trials
Available clinical trial counts are calculated from public registries and may change at any time. Counts shown on the page follow the most recent registry data imported.
NCT04728893Phase 2Combination regimen
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
United States, Argentina, Australia +19121 registry sites
Why this appears: Appears because it is recorded for Lymphoma.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04728893Not verified
NCT05139017Phase 2 / Phase 3Immunotherapy
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Lymphoma | Immunotherapy, Chemotherapy
United States, Argentina, Australia +23135 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05139017Not verified
NCT05947851Phase 3Combination regimen
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Lymphoma | Immunotherapy, Targeted therapy
United States, Argentina, Australia +1999 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05947851Not verified
NCT06124157Phase 2Combination regimen
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Lymphoma | Targeted therapy, Radiotherapy, Chemotherapy
United States, Australia, Canada +1159 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06124157Not verified
What needs confirmation
- • Visa, stay permit, and entry requirements for medical care must be checked through official government and embassy channels. TanyaKanker does not guarantee acceptance.
- • Service availability, written estimate, inclusions and exclusions.
- • Follow-up plan after returning to Indonesia.
Ask about access in Australia
Organise the case and questions without promises of acceptance, price, or treatment outcome.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.